"Whatever stage of the journey you’re on, we’re here to help build better medicines together"

About us

About us

Bencard Adjuvant Systems is a division of Allergy Therapeutics UK; a fully integrated, speciality pharmaceutical company. Allergy Therapeutics plc is listed on the London Stock Exchange; AIM ticker AGY.

Located in Worthing, on England’s south coast, Bencard Adjuvant Systems specialise in developing and optimising adjuvants for infectious diseases, cancer immunotherapy and allergen immunotherapy.

We at Bencard Adjuvant Systems are committed to engaging in long-term partnerships with those who require our patented platform of adjuvant technologies to enable successful vaccine or immunotherapy development.

Learn more

In addition to providing novel, safe and efficacious adjuvant platforms, Bencard Adjuvant Systems have over 70 years of experience in manufacture, QC testing, regulatory filing and compliance.What ever your project, we can build better medicines together! Bencard Adjuvant Systems have an adjuvant portfolio that considers optimal immunogenicity and clinical relevance of antibody response.

Our adjuvant technologies are readily adaptable and offer optimal flexibility. Our people have a wealth of intellect to help you develop the best vaccines for efficacy and safety.

Bencard - Biological Activity - Physiochemical Propities
DNA Strand

Microcrystalline Tyrosine

Microcrystalline Tyrosine

  • Naturally metabolised
  • Extensive in humans
  • Established antigen binding capacity
  • Potent immune system potentiator
BAS Gamma


  • Dual power of MCT and Virus-like particles(VLP)
  • Potential to enhance weakly reactive vaccine candidates
  • VLP induces strong humoral and cellular immune responses
  • MCT-VLP induces higher protective cellular immunity compared with other adjuvants
BAS Beta



Phosphatidylserine derivatives effect different antibody subclasses and their levels.
  • DOPS – stimulator of IgG
  • LOPS – stimulator of IgA
  • SAPS – inhibitor of IgE
AdSys-PS exhibit no mutagenic properties or cytotoxic effects.

Microcrystalline tyrosine(MCT ®): A depot adjuvant in licensed allergy immunotherapy offers new opportunities in Malaria.

G. Cabral-Miranda, et al. Vaccines 2017, 5(4), 32.

Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax

G. Cabral-Miranda, et al. Vaccines 2017, 5(2), 10

Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza

M.D. Heath, et al. BMC Infectious Diseases (2017) 17:232

Clinical use of adjuvants in allergen immunotherapy

L. Klimek, et al. Expert Review of Clinical Immunology, 2017, 13:6, 599-610

Analysis of aluminium in rat following administration of allergen immunotherapy using either aluminium or microcrystalline-tyrosine-based adjuvants

S. A. McDougall, et al. Bioanalysis (2016) 8(6), 547–556

The adsorption of allergoids and 3-0-desacyl-4'-monophosphoryl lipid A (MPL®) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy.

A.J. Bell, et al. Journal of Inorganic Biochemistry 152 (2015) 147–153

Contact us

Feel free to contact us if you have any questions

This website uses cookies to ensure you get the best experience on our website.

Read more

Reject Cookies Accept Cookies